Clinical Trials Directory

Trials / Completed

CompletedNCT01057407

A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
110 (actual)
Sponsor
Astellas Pharma Inc · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

This is a multi-center, open-labeled study to examine the non-inferiority of ASP1585 to sevelamer hydrochloride in chronic kidney disease patients with hyperphosphatemia on hemodialysis.

Conditions

Interventions

TypeNameDescription
DRUGASP1585oral
DRUGSevelamer hydrochlorideoral

Timeline

Start date
2010-01-01
Primary completion
2010-09-01
Completion
2010-09-01
First posted
2010-01-27
Last updated
2015-05-04

Locations

3 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT01057407. Inclusion in this directory is not an endorsement.